Cotinga Pharmaceuticals Inc. (COTQF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2018 | 927.96 Thousand USD | -22.37% |
| 2017 | 1.19 Million USD | -59.41% |
| 2016 | 2.94 Million USD | -46.25% |
| 2015 | 5.47 Million USD | 89.95% |
| 2014 | 2.88 Million USD | 25.15% |
| 2013 | 2.3 Million USD | 2.87% |
| 2012 | 2.24 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2019 Q2 | 715.63 USD | -6.02% |
| 2019 Q1 | 761.50 USD | -18.27% |
| 2019 Q3 | 687.38 USD | -3.95% |
| 2018 Q3 | 1054.07 USD | -3.65% |
| 2018 Q4 | 931.76 USD | -11.6% |
| 2018 Q2 | 1094.04 USD | -29.51% |
| 2018 Q1 | 1552.03 USD | 30.03% |
| 2018 FY | 927.96 Thousand USD | -22.37% |
| 2017 FY | 1.19 Million USD | -59.41% |
| 2017 Q4 | 1193.57 USD | -23.81% |
| 2017 Q3 | 1566.67 USD | -31.73% |
| 2017 Q2 | 2294.66 USD | 11.04% |
| 2017 Q1 | 2066.50 USD | -29.95% |
| 2016 Q4 | 2950.04 USD | -29.6% |
| 2016 Q2 | 4897.20 USD | -14.93% |
| 2016 Q3 | 4190.19 USD | -14.44% |
| 2016 FY | 2.94 Million USD | -46.25% |
| 2016 Q1 | 5756.47 USD | 5.18% |
| 2015 Q3 | 2579.66 USD | -17.75% |
| 2015 FY | 5.47 Million USD | 89.95% |
| 2015 Q2 | 3136.21 USD | -10.84% |
| 2015 Q4 | 5472.74 USD | 112.15% |
| 2015 Q1 | 3517.36 USD | 21.94% |
| 2014 Q3 | 3067.73 USD | 43.94% |
| 2014 FY | 2.88 Million USD | 25.15% |
| 2014 Q2 | 2131.26 USD | -9.59% |
| 2014 Q4 | 2884.57 USD | -5.97% |
| 2014 Q1 | 2357.28 USD | 2.27% |
| 2013 Q4 | 2304.91 USD | 16.66% |
| 2013 FY | 2.3 Million USD | 2.87% |
| 2013 Q3 | 1975.68 USD | -26.95% |
| 2013 Q2 | 2704.73 USD | 22.94% |
| 2013 Q1 | 2199.98 USD | -1.81% |
| 2012 Q2 | 2768.07 USD | 0.0% |
| 2012 Q3 | 2670.90 USD | -3.51% |
| 2012 Q4 | 2240.61 USD | -16.11% |
| 2012 FY | 2.24 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -40071.472% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 52.611% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 91.207% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -68.072% |
| Rebus Holdings, Inc. | 5000.00 USD | -18459.22% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.287% |
| Qrons Inc. | 420.00 USD | -220843.095% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -20.414% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 96.679% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -93.101% |
| Skye Bioscience, Inc. | 11.94 Million USD | 92.228% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 97.611% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 87.147% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1115.34% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.134% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 35.2% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1182.334% |
| Mesoblast Limited | 667.9 Million USD | 99.861% |
| Marizyme, Inc. | 22.01 Million USD | 95.785% |
| Genus plc | 1.02 Billion USD | 99.91% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 31.685% |
| Pharming Group N.V. | 462.85 Million USD | 99.8% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 71.99% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -85.95% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -48.0% |
| ContraFect Corporation | 20.67 Million USD | 95.513% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -137.716% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -142.809% |
| IMV Inc. | 31.33 Million USD | 97.038% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 77.618% |
| MultiCell Technologies, Inc. | 126.22 USD | -735093.313% |
| ONE Bio Corp. | 70.08 Million USD | 98.676% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 1.248% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.278% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -114.948% |
| Q BioMed Inc. | 3.51 Million USD | 73.604% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 97.362% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -255.164% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1157.076% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.792% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 35.952% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 96.908% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 66.211% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -34.979% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 64.353% |
| GB Sciences, Inc. | 103.44 Thousand USD | -797.083% |
| Alpha Cognition Inc. | 2.45 Million USD | 62.158% |
| HST Global, Inc. | 1526.00 USD | -60710.026% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 6.074% |
| Halberd Corporation | 10.13 Thousand USD | -9059.619% |
| Enzolytics Inc. | 361.7 Million USD | 99.743% |
| Agentix Corp. | 261.39 Thousand USD | -255.007% |
| Resverlogix Corp. | 8.11 Million USD | 88.565% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 50.585% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.98% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.055% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -45.072% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -3973.399% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 89.631% |
| AVAX Technologies, Inc. | 7.37 Million USD | 87.421% |
| Zenith Capital Corp. | 7410.00 USD | -12423.09% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.973% |
| Ember Therapeutics, Inc. | 184.00 USD | -504226.63% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -188.36% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -255.045% |
| Kadimastem Ltd | 2.3 Million USD | 59.725% |
| Helix BioMedix, Inc. | 3.02 Million USD | 69.324% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 98.239% |
| BioStem Technologies, Inc. | 14.56 Million USD | 93.627% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1525.321% |
| LadRx Corporation | 2.3 Million USD | 59.792% |
| Cell Source, Inc. | 195.17 Thousand USD | -375.46% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -162.42% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -162.42% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1390.748% |
| Affymax, Inc. | 7.44 Million USD | 87.532% |
| Itoco Inc. | 1.4 Million USD | 33.72% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -870.092% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -775.435% |
| Mobile Lads Corp. | 52.00 USD | -1784440.385% |
| CytoDyn Inc. | 11.13 Million USD | 91.667% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -549.051% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -5089.938% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -140.734% |
| SYBLEU INC | 330.46 Thousand USD | -180.802% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -126.651% |
| International Stem Cell Corporation | 5.39 Million USD | 82.784% |
| Bioxytran, Inc. | 137.63 Thousand USD | -574.204% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 93.814% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 94.403% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1074.634% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -7.319% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 87.655% |
| Neutra Corp. | 2851.00 USD | -32448.615% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 97.136% |
| PureTech Health plc | 693.97 Million USD | 99.866% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 88.503% |
| IXICO plc | 15.84 Million USD | 94.143% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 88.795% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.102% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Cellectis S.A. | 333.99 Million USD | 99.722% |